WASHINGTON, DC--(Marketwired - May 7, 2013) - England & Company, a middle-market merchant bank, announced today that Gary Lessing has joined the firm as a Managing Director in its Washington, DC office.
Mr. Lessing, previously a Managing Director in Healthcare Investment Banking at Deutsche Banc Alex. Brown, will provide strategic advice to a broad range of healthcare clients, including healthcare services, medical device, and biotechnology companies.
"Gary will add significant expertise to our growing healthcare platform," said Craig England, CEO of England & Company. "This sector is core to our investment banking business. Gary's deep industry relationships and experience, both as an advisor to the industry's most prominent companies and as an entrepreneur in his own right, will be invaluable as we continue to expand our healthcare franchise."
Prior to joining England & Company, Mr. Lessing was a Managing Director in the Healthcare Investment Banking Group at Deutsche Banc Alex. Brown (DBAB) and its predecessor, Alex. Brown & Sons, Inc. He also served as head of the firm's European Healthcare Investment Banking Group. Following his tenure at DBAB, Mr. Lessing served as Executive Vice President and Chief Financial Officer of Avalon Pharmaceuticals, Inc., co-founder and Chief Executive Officer of Corridor Pharmaceuticals, Inc. (fka Arginetix, Inc.), and Chairman of the Board of Topigen Pharmaceuticals, Inc.
England & Company (www.englandco.com) is dedicated to providing the highest quality investment banking services and value-added capital to middle-market companies and their financial sponsors. With offices in New York and Washington, DC, England Securities advises clients on strategic initiatives, including mergers, acquisitions, financial restructurings, and capital formation. England Capital Partners (ECP) invests in partnership with leading private equity firms and exceptional management teams where ECP's expertise, industry knowledge, and strong network of resources complement growth strategies to accelerate a company's long-term value.